Processa Pharmaceuticals, Inc. Deferred Tax Assets, Tax Credit Carryforwards, General Business
Processa Pharmaceuticals, Inc. (PCSA) had Deferred Tax Assets, Tax Credit Carryforwards, General Business of $3.17 million as of 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness · last filed 2022-03-30
- 2021-12-31: Deferred Tax Assets, Tax Credit Carryforwards, General Business $3.17M.
- 2020-12-31: Deferred Tax Assets, Tax Credit Carryforwards, General Business $1.35M.
- 2019-12-31: Deferred Tax Assets, Tax Credit Carryforwards, General Business $2.91M.
- 2018-12-31: Deferred Tax Assets, Tax Credit Carryforwards, General Business $1.70M.
| Period end | Deferred Tax Assets, Tax Credit Carryforwards, General Business |
|---|---|
| 2021-12-31 | $3.17M 10-K · filed 2022-03-30 |
| 2020-12-31 | $1.35M 10-K · filed 2022-03-30 |
| 2019-12-31 | $2.91M 10-K · filed 2020-03-06 |
| 2018-12-31 | $1.70M 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |